ARD-61 是一种高效、特异的 PROTAC 雄激素受体 (AR) 降解剂,可有效诱导 AR+ 癌细胞系中 AR 和孕酮受体 (PR) 的降解,诱导细胞凋亡,并有效抑制小鼠 MDA-MB-453 异种移植模型中的肿瘤生长。
产品编号: MS-C62035 纯度: 99.57% CAS No.: 2316837-08-6 分子式: C61H71ClN8O7S 分子量: 1095.78
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

ARD-61 是一种高效、特异的 PROTAC 雄激素受体 (AR) 降解剂,可有效诱导 AR+ 癌细胞系中 AR 和孕酮受体 (PR) 的降解,诱导细胞凋亡,并有效抑制小鼠 MDA-MB-453 异种移植模型中的肿瘤生长。

生物实验数据

生物活性 ARD-61 is a highly potent and specific PROTAC androgen receptor (AR) degrader that effectively induces the degradation of AR and progesterone receptor (PR) in AR+ cancer cell lines, induces apoptosis, and effectively inhibits tumor growth in the mouse MDA-MB-453 xenograft model.
IC50 & Target

VHL

 

体外研究
(In Vitro)

ARD-61 binds to AR protein through its AR antagonist portion and von Hippel-Lindau (VHL)/cullin 2 E3 ligase through its VHL ligand portion to recruit AR protein to cullin 2 for ubiquitination, followed by proteasome-dependent AR degradation.
ARD-61 (0.001-100 μM; for 7?days) has IC50 values of 235?nM and 121?nM in the MDA-MB-453 and HCC1428 cell lines, which have the highest AR expression, respectively. ARD-61 demonstrates partial cell growth inhibition, delivering IC50 values of 39, 147, and 380?nM, respectively, in the MCF-7, BT-549 and MDA-MB-415 cell lines, which have a moderate level of AR protein.
ARD-61 (25-100000 nM; 6-72 h) induces G2/M cell cycle arrest in a dose- and time-dependent manner in each of these three AR+ breast cancer cell lines.
ARD-61 (25-100000 nM; 72 h) induces apoptosis in the MDA-MB-453 and HCC1428 cell lines.
ARD-61 (0.01-1000 nM; 6 h) is highly potent and effective in reducing AR protein levels. ARD-61 (0.01-1000 nM; 24 h) reduces the level of PR protein with a DC50 value of 0.15?nM in the T47D cells. ARD-61 has no obvious effect on ER and GR proteins.
ARD-61 (1?μM; for 24?h) effectively inhibits Wnt/β-catenin and MYC signaling pathways. ARD-61 (1-1000?nM; for 24?h) not only decreases both phosphorylated HER2 and HER3, but also un-phosphorylated HER2 and HER3 proteins.
Efficient knock-down of VHL completely blocks AR degradation induced by ARD-61 (100?nM; 24 h) in both MDA-MB-453 and MCF-7 cell lines.

Cell Viability Assay

Cell Line: MDA-MB-453 and HCC1428 cell lines
Concentration: 0.001, 0.01, 0.1, 1, 10, 100 μM
Incubation Time: 7 days
Result: Achieves near complete inhibition of cell growth.

Cell Cycle Analysis

Cell Line: MDA-MB-453, HCC1428 and MCF-7 cell lines
Concentration: 25, 250, 500, 1000, 10000, 100000 nM
Incubation Time: 6-72 hours
Result: Induced G2/M cell cycle arrest in a dose- and time-dependent manner in each of these three AR+ breast cancer cell lines.

Apoptosis Analysis

Cell Line: MDA-MB-453 and HCC1428 cell lines
Concentration: 25, 250, 500, 1000, 10000, 100000 nM
Incubation Time: 6-72 hours
Result: Induced apoptosis in the MDA-MB-453 and HCC1428 cell lines in a dose-dependent manner.

Western Blot Analysis

Cell Line: MDA-MB-453, MCF-7, BT549, MDA-MB-415 and HCC1428 cell lines
Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM
Incubation Time: 6 hours
Result: Reduced AR protein levels in the MDA-MB-453 (DC50=0.44 nM), MCF-7 (DC50=1.8 nM), BT549 (DC50=2.0 nM), MDA-MB-415 (DC50=2.4 nM) and HCC1428 (DC50=3.0 nM) cell lines.
体内研究
(In Vivo)

ARD-61 (25, 50?mg/kg/day; ip; for 75 days) effectively inhibits tumor growthin the MDA-MB-453 xenograft tumor model in male SCID mice.
ARD-61 (25?mg/kg; ip; single dose) effectively and rapidly reduces the AR protein in the MDA-MB-453 xenograft tissue, with the effect persisting for at least 24?h. ARD-61 is very effective in reducing the mRNA level of WNT7B in a time-dependent manner.

Animal Model: MDA-MB-453 xenograft tumor model in male SCID mice
Dosage: 25, 50 mg/kg
Administration: IP; daily; for 75 days
Result: Effectively inhibited tumor growth.
性状 固体
颜色 White to light yellow

化学信息

分子量 1095.78
分子式 C61H71ClN8O7S
CAS No. 2316837-08-6

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (91.26 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.9126 mL4.5630 mL9.1259 mL22.8148 mL
5 mM0.1825 mL0.9126 mL1.8252 mL4.5630 mL
10 mM0.0913 mL0.4563 mL0.9126 mL2.2815 mL
15 mM0.0608 mL0.3042 mL0.6084 mL1.5210 mL
20 mM0.0456 mL0.2281 mL0.4563 mL1.1407 mL
25 mM0.0365 mL0.1825 mL0.3650 mL0.9126 mL
30 mM0.0304 mL0.1521 mL0.3042 mL0.7605 mL
40 mM0.0228 mL0.1141 mL0.2281 mL0.5704 mL
50 mM0.0183 mL0.0913 mL0.1825 mL0.4563 mL
60 mM0.0152 mL0.0760 mL0.1521 mL0.3802 mL
80 mM0.0114 mL0.0570 mL0.1141 mL0.2852 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础